Related references
Note: Only part of the references are listed.Tumor resistance to anti-VEGF therapy through up-regulation of VEGF-C expression
Dong Li et al.
CANCER LETTERS (2014)
VEGF-C mediates RhoGDI2-induced gastric cancer cell metastasis and cisplatin resistance
Hee Jun Cho et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity
Leibo Xu et al.
JOURNAL OF HEPATOLOGY (2014)
VEGFR3 Inhibition Chemosensitizes Ovarian Cancer Stemlike Cells through Down-Regulation of BRCA1 and BRCA2
Jaeyoung J. Lim et al.
NEOPLASIA (2014)
MicroRNA-101 suppresses motility of bladder cancer cells by targeting c-Met
Zhenghui Hu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2013)
MiR-101 inhibits melanoma cell invasion and proliferation by targeting MITF and EZH2
Chonglin Luo et al.
CANCER LETTERS (2013)
Structural and mechanistic insights into VEGF receptor 3 ligand binding and activation
Veli-Matti Leppanen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer
Kristina Schee et al.
BMC CANCER (2012)
miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer
Iver Nordentoft et al.
BMC MEDICAL GENOMICS (2012)
Molecular mechanisms of cisplatin resistance in bladder cancer
Ross M. Drayton et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2012)
MiR-101 and Mcl-1 in non-small-cell lung cancer: expression profile and clinical significance
Liang Luo et al.
MEDICAL ONCOLOGY (2012)
Reference miRNAs for miRNAome Analysis of Urothelial Carcinomas
Nadine Ratert et al.
PLOS ONE (2012)
MiR-101 Is Involved in Human Breast Carcinogenesis by Targeting Stathmin1
Rui Wang et al.
PLOS ONE (2012)
Enforced Expression of miR-101 Inhibits Prostate Cancer Cell Growth by Modulating the COX-2 Pathway In Vivo
Yubin Hao et al.
CANCER PREVENTION RESEARCH (2011)
MicroRNA EXPRESSION PROFILES OF HEAD AND NECK SQUAMOUS CELL CARCINOMA WITH DOCETAXEL-INDUCED MULTIDRUG RESISTANCE
Yuemeng Dai et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2011)
FGF-2 Regulates Cell Proliferation, Migration, and Angiogenesis through an NDY1/KDM2B-miR-101-EZH2 Pathway
Filippos Kottakis et al.
MOLECULAR CELL (2011)
Lymphangiogenesis: Molecular Mechanisms and Future Promise
Tuomas Tammela et al.
CELL (2010)
MicroRNA-101 is down-regulated in gastric cancer and involved in cell migration and invasion
Hui-Ju Wang et al.
EUROPEAN JOURNAL OF CANCER (2010)
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Long-term results of combined chemotherapy with gemcitabine and cisplatin for metastatic urothelial carcinomas
Nozomu Tanji et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2010)
Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium
Guru Sonpavde et al.
LANCET ONCOLOGY (2010)
The Putative Tumor Suppressor microRNA-101 Modulates the Cancer Epigenome by Repressing the Polycomb Group Protein EZH2
Jeffrey M. Friedman et al.
CANCER RESEARCH (2009)
MicroRNA-101, Down-regulated in Hepatocellular Carcinoma, Promotes Apoptosis and Suppresses Tumorigenicity
Hang Su et al.
CANCER RESEARCH (2009)
MicroRNAs: Target Recognition and Regulatory Functions
David P. Bartel
CELL (2009)
Outcome of Patients With Bladder Cancer With pN plus Disease After Preoperative Chemotherapy and Radical Cystectomy
Wassim Kassouf et al.
UROLOGY (2009)
The presence of lymphovascular invasion in radical cystectomy specimens from patients with urothelial carcinoma portends a poor clinical prognosis
Daniel Canter et al.
BJU INTERNATIONAL (2008)
Adjuvant chemotherapy for bladder cancer does not alter cancer-specific survival after cystectomy in a matched case-control study
Jochen Walz et al.
BJU INTERNATIONAL (2008)
The role of the lymphatic system and its specific growth factor, vascular endothelial growth factor C, for lymphogenic metastasis in prostate cancer
Lutz Trojan et al.
BJU INTERNATIONAL (2006)
The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells
JL Su et al.
CANCER CELL (2006)
Update on chemotherapy for advanced bladder cancer
JE Rosenberg et al.
JOURNAL OF UROLOGY (2005)
Vascular endothelial growth factor-C (VEGF-C) expression predicts lymph node metastasis of transitional cell carcinoma of the bladder
K Suzuki et al.
INTERNATIONAL JOURNAL OF UROLOGY (2005)
Transitional cell carcinoma of the urinary bladder with regional lymph node involvement treated by cystectomy - Clinicopathologic features associated with outcome
I Frank et al.
CANCER (2003)
Prognostic significance of vascular and perineural invasion in urothelial bladder cancer treated with radical cystectomy
J Leissner et al.
JOURNAL OF UROLOGY (2003)
Transurethral resection of muscle-invasive bladder cancer: 10-year outcome
HW Herr
JOURNAL OF CLINICAL ONCOLOGY (2001)
Vascular endothelial growth factor-C (VEGF-C) expression in human colorectal cancer tissues
K Akagi et al.
BRITISH JOURNAL OF CANCER (2000)
Share Paper
